Characterization of a humanized monoclonal antibody recognizing clumping factor A expressed by Staphylococcus aureus.
about
Investigational drugs to treat methicillin-resistant Staphylococcus aureusA Structural Model of the Staphylococcus aureus ClfA–Fibrinogen Interaction Opens New Avenues for the Design of Anti-Staphylococcal TherapeuticsA recombinant clumping factor A-containing vaccine induces functional antibodies to Staphylococcus aureus that are not observed after natural exposureIdentification of antigenic components of Staphylococcus epidermidis expressed during human infection.Progress in the development of effective vaccines to prevent selected gram-positive bacterial infections.Characterization of the opsonic and protective activity against Staphylococcus aureus of fully human monoclonal antibodies specific for the bacterial surface polysaccharide poly-N-acetylglucosamine.Induction of experimental endocarditis by continuous low-grade bacteremia mimicking spontaneous bacteremia in humans.Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremiaHuman monoclonal single-chain antibodies specific to dengue virus envelope protein.Phase I dose escalation study to evaluate the safety and pharmacokinetic profile of tefibazumab in subjects with end-stage renal disease requiring hemodialysisSynthesis and evaluation of a conjugate vaccine composed of Staphylococcus aureus poly-N-acetyl-glucosamine and clumping factor A.Protective efficacy of the chimeric Staphylococcus aureus vaccine candidate IC in sepsis and pneumonia modelsPhosphatidylserine exposure on the surface of Leishmania amazonensis amastigotes modulates in vivo infection and dendritic cell function.Staphylococcus aureus Clumping Factor A Remains a Viable Vaccine Target for Prevention of S. aureus Infection.Antibodies to capsular polysaccharide and clumping factor A prevent mastitis and the emergence of unencapsulated and small-colony variants of Staphylococcus aureus in mice.Structural and functional role of Staphylococcus aureus surface components recognizing adhesive matrix molecules of the host.Advances in the diagnosis and management of pediatric osteomyelitis.Diabetic foot infections: microbiological aspects, current and future antibiotic therapy focusing on methicillin-resistant Staphylococcus aureus.Adaptive Immunity Against Staphylococcus aureus.Staphylococcus aureus Aggregation and Coagulation Mechanisms, and Their Function in Host-Pathogen Interactions.Role of interleukin-17A in cell-mediated protection against Staphylococcus aureus infection in mice immunized with the fibrinogen-binding domain of clumping factor A.An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity.A multifunctional bispecific antibody against Pseudomonas aeruginosa as a potential therapeutic strategy.MEDI3902 correlates of protection against severe Pseudomonas aeruginosa pneumonia in a rabbit acute pneumonia model.Protective immunization against Staphylococcus aureus infection in a novel experimental wound model in mice.
P2860
Q26780246-7F5380BA-6A0F-47FB-8F34-4ABD64BDAFD9Q27653017-F22139D5-C9EC-419D-9002-64E34E73DCBBQ28714292-F27B4B38-BD78-402B-A80D-FAB47E85DAF7Q33251441-09AC3599-E3F4-4FC2-96D8-F2C515943FC2Q34112608-112EADAB-E3A9-437F-8647-B6EECEC86D4AQ34601937-5291F4C9-1B70-4AC0-AA1F-05A8B2E0FE28Q34931562-87A70B50-8642-4C95-82C5-DBDADC394742Q34973729-409499B8-3FE8-41B2-9D59-2E356AC5AAF9Q35050826-941A8B50-1319-4AC5-8F98-A7699FB0E849Q35091505-23ABCC08-D496-4FD1-A796-749CD4434EE3Q36213353-B7BDA650-1C6C-47E9-A5D5-3DEE06FF094AQ36569841-86A6AB38-B4CC-4BBD-B4AF-AE98D054FC36Q36589026-EBCE8376-E840-47AC-8D84-8642C77BC110Q36736262-9E930FE4-B011-45FA-8875-43C1344D53F8Q36974423-433C8B56-C5C5-4D7E-941D-C2D68DC85DE0Q37648719-F5E05D90-0018-4A44-A73D-FED1F7323243Q37905654-5331B30E-4597-4E1C-89C3-BD99579A15DDQ37924980-49FE39F7-7976-447E-98C8-71F85A944F23Q38751767-55398426-B607-4449-9965-2899F854E651Q38938178-4A09B445-5ADC-4E3F-ABA9-D16BD8C82D3EQ42116946-5EF69DB1-CCD7-4F2D-B38B-B9B965282F2AQ42906503-1D8F4FF3-A1E3-45DB-9009-151C9B4B8E80Q43083370-6E5D8837-375C-4D8C-8550-856BF6A325A4Q51747341-16901120-81C4-47E0-BC0A-5226E114BD86Q54328600-282A585F-FE67-4D87-B309-2C1F9FA976BF
P2860
Characterization of a humanized monoclonal antibody recognizing clumping factor A expressed by Staphylococcus aureus.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Characterization of a humanize ...... ssed by Staphylococcus aureus.
@ast
Characterization of a humanize ...... ssed by Staphylococcus aureus.
@en
type
label
Characterization of a humanize ...... ssed by Staphylococcus aureus.
@ast
Characterization of a humanize ...... ssed by Staphylococcus aureus.
@en
prefLabel
Characterization of a humanize ...... ssed by Staphylococcus aureus.
@ast
Characterization of a humanize ...... ssed by Staphylococcus aureus.
@en
P2093
P2860
P1476
Characterization of a humanize ...... ssed by Staphylococcus aureus.
@en
P2093
Andrea E Hall
Arnold S Bayer
Dawn Bryant
Elena L Gorovits
Jeff T Hutchins
John H Vernachio
Joseph M Patti
Paul J Domanski
Peter J Syribeys
P2860
P304
P356
10.1128/IAI.73.8.5229-5232.2005
P407
P577
2005-08-01T00:00:00Z